A. Observed frequencies (n) and overall differences (Fisher’s exact test) in incidence of peri-bladder artefacts between the cohorts. Results from post hoc pairwise Z-tests with Bonferroni correction for multiple testing are shown as p values per cohort | |||||||
---|---|---|---|---|---|---|---|
Type, severity | G− | G+ | F− | F+ | totals | ||
Peri-bladder artefacts | Yes (any) | 9 | 1 | 26 | 6 | 42 | |
Halo, mild | 6 | 1 | 8 | 2 | 17 | ||
Halo, severe | 1 | 0 | 14 | 0 | 15 | ||
Flare, mild | 8 | 1 | 10 | 6 | 25 | ||
Flare, severe | 1 | 0 | 14 | 0 | 15 | ||
No | 42 | 49 | 25 | 44 | 160 | ||
P value | 1.000 | 0.001 | < 0.001 | 0.310 |
B. Concordance of incidence, type, and severity of peri-bladder artefacts | ||||
---|---|---|---|---|
Peri-bladder artefacts | Halo | |||
No | Mild | Severe | ||
Flare | No | 160 | 2 | 0 |
Mild | 10 | 13 | 2 | |
Severe | 0 | 2 | 13 |
C. Logistic regression analysis assessing the relation between administration of furosemide or choice of tracer on the incidence of peri-bladder artefacts | ||||
---|---|---|---|---|
B | SE | Odds ratio (95% CI) | P value | |
Variables | ||||
Radiopharmaceutical | 1.887 | 1.296 | 6.602 (0.520–83.760) | 0.145 |
Furosemide | − 1.500 | 1.348 | 0.223 (0.016–3.130) | 0.266 |
SUVmax bladder | 0.074 | 0.035 | 1.077 (1.006–1.153) | 0.033 |
Interaction effects | ||||
SUVmax bladder * radiopharmaceutical | − 0.017 | 0.019 | 0.983 (0.947–1.021) | 0.378 |
SUVmax bladder * furosemide | 0.038 | 0.029 | 1.038 (0.981–1.099) | 0.196 |